[{"id":"6b3ea990-8167-4dc6-ab05-279352bba7ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03875079","created_at":"2021-01-18T19:06:21.197Z","updated_at":"2024-07-02T16:35:52.073Z","phase":"Phase 1","brief_title":"A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma","source_id_and_acronym":"NCT03875079","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • BRAF • CD8 • FOXP3","pipe":" | ","alterations":" BRAF mutation","tags":["PD-L1 • BRAF • CD8 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • simlukafusp alfa (RG7461)"],"overall_status":"Completed","enrollment":" Enrollment 83","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 07/14/2022","primary_completion_date":" 07/14/2022","study_txt":" Completion: 07/14/2022","study_completion_date":" 07/14/2022","last_update_posted":"2023-03-29"},{"id":"37a4bacd-4a1a-4ca6-b11b-c51612a5ace1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03063762","created_at":"2021-01-18T15:05:33.057Z","updated_at":"2024-07-02T16:35:55.224Z","phase":"Phase 1b","brief_title":"Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)","source_id_and_acronym":"NCT03063762","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • simlukafusp alfa (RG7461)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 03/20/2017","start_date":" 03/20/2017","primary_txt":" Primary completion: 06/14/2021","primary_completion_date":" 06/14/2021","study_txt":" Completion: 06/14/2021","study_completion_date":" 06/14/2021","last_update_posted":"2023-02-17"},{"id":"e871cbb4-11ae-42b0-a2ff-04f0f7366402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02627274","created_at":"2021-01-18T12:46:07.584Z","updated_at":"2024-07-02T16:36:00.068Z","phase":"Phase 1a/1b","brief_title":"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)","source_id_and_acronym":"NCT02627274","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" EGFR positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Erbitux (cetuximab) • simlukafusp alfa (RG7461)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 12/07/2015","start_date":" 12/07/2015","primary_txt":" Primary completion: 11/10/2022","primary_completion_date":" 11/10/2022","study_txt":" Completion: 11/10/2022","study_completion_date":" 11/10/2022","last_update_posted":"2022-11-22"}]